Karyopharm Therapeutics Inc. Cost of Revenue
Karyopharm Therapeutics Inc. (KPTI) reported Cost of Revenue of $1.01 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-04.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-11-04
- Karyopharm Therapeutics Inc. cost of goods and services sold for the quarter ending 2019-09-30 was $1.01M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 9 month |
|---|---|---|
| 2019-09-30 | $1.01M 10-Q · filed 2019-11-04 | $1.01M 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |